Paul Josephs, DPT's SVP, sales, Marketing & Corporate Development, spoke with Outsourcing-Pharma.com after the San Antonio contract manufacturing organization (CMO) announced it had started ‘integrating’ with fellow Renaissance Acquisition Holdings owned contractor Confab earlier this week.
He told us that – following Boehringer Ingelheim’s announcement that it will close fellow sterile injectables manufacturer Ben Venue by the end of the year – DPT “are fielding calls and inquiries from some of their customers and evaluating next steps.”
Further details of these evaluations were not provided.
DPT’s capabilities in sterile manufacturing - as well as its sales and marketing clout – were also key to owner Renaissance Pharma’s decision to forge closer tied between the Texan firm and Canadian counterpart Confab, according to Josephs.
“DPT and Confab will continue to focus in non-sterile semi-solid, liquid and solids markets, along with our aggressive focus on sterile semi-solid and liquid opportunities.
He added that: “Being that DPT and Confab are both in the CDMO market, it makes sense to leverage the management strength of both companies by working collaboratively” explaining that DPT’s sales and marketing team will help broaden Confab’s recognition and increase growth in the US.
Josephs also confirmed that “no staff cuts or facility divestitures planned at this time” going on to say that “this is an integration between DPT and Confab, this will be an on-going process, without a completion date.”
He added that post integration DPT and Confab will keep their respective names and logos. Paul Johnson will lead the group but the management teams will remain the same.
“The step that is most visible will be the integrated promotion of Confab services into DPT’s existing sales and marketing team.”